Do you offer consolidation durvalumab in a patient who had pneumonitis requiring steroids following chemoradiation for LS-SCLC?

In the ADRIATIC trial, pneumonitis or radiation pneumonitis occurred in 38.2% of durvalumab-treated patients, and 8.8% discontinued treatment due to pneumonitis (Cheng et al., PMID 39268857). While there is emerging interest in immune checkpoint inhibitor rechallenge after successful management of i...

The ADRIATIC trial with the addition of consolidative durvalumab for 24 months showed significant improvement in OS and PFS in LS-SCLC. The median survival was improved from 33.4 months with placebo to 55.9 months with durva (HR 0.73, p=0.01), and PFS was improved from 9.2 months w/o durva to 16.6 m...